FIDAXOMICIN - Generic Drug Details

What are the generic drug sources for fidaxomicin and what is the scope of patent protection?

Fidaxomicin is the generic ingredient in two branded drugs marketed by Cubist Pharms Llc, Actavis Labs Fl, Apotex, and Torrent, and is included in five NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fidaxomicin has one hundred and fifty-eight patent family members in thirty-six countries.

There are two drug master file entries for fidaxomicin. Four suppliers are listed for this compound.

Summary for FIDAXOMICIN

International Patents:	158
US Patents:	5
Tradenames:	2
Applicants:	4
NDAs:	5
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	41
Clinical Trials:	43
Patent Applications:	2,542
Drug Prices:	Drug price trends for FIDAXOMICIN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FIDAXOMICIN
What excipients (inactive ingredients) are in FIDAXOMICIN?	FIDAXOMICIN excipients list
DailyMed Link:	FIDAXOMICIN at DailyMed

See drug prices for FIDAXOMICIN

Recent Clinical Trials for FIDAXOMICIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE3
Medical College of Wisconsin	EARLY_PHASE1
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE2

See all FIDAXOMICIN clinical trials

Pharmacology for FIDAXOMICIN

Drug Class

Macrolide Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for FIDAXOMICIN

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for FIDAXOMICIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DIFICID	Tablets	fidaxomicin	200 mg	201699	1	2015-05-27

US Patents and Regulatory Information for FIDAXOMICIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cubist Pharms Llc	DIFICID	fidaxomicin	TABLET;ORAL	201699-001	May 27, 2011	AB	RX	Yes	Yes	7,863,249*PED				Y
Cubist Pharms Llc	DIFICID	fidaxomicin	FOR SUSPENSION;ORAL	213138-001	Jan 24, 2020		RX	Yes	Yes	9,808,530*PED				Y
Apotex	FIDAXOMICIN	fidaxomicin	TABLET;ORAL	219559-001	Feb 2, 2026	AB	RX	No	No
Cubist Pharms Llc	DIFICID	fidaxomicin	TABLET;ORAL	201699-001	May 27, 2011	AB	RX	Yes	Yes	7,906,489*PED				Y

EU/EMA Drug Approvals for FIDAXOMICIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Tillotts Pharma GmbH	Dificlir	fidaxomicin	EMEA/H/C/002087Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.Dificlir granules for oral suspension is indicated for the treatment of Clostridioides  difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.	Authorised	no	no	no	2011-12-05

International Patents for FIDAXOMICIN

Country	Patent Number	Title	Estimated Expiration
Mexico	340742	COMPUESTOS MACROCICLICOS DE 18 MIEMBROS Y ANALOGOS DE LOS MISMOS. (18-MEMBERED MACROCYCLES AND ANALOGS THEREOF.)
Denmark	2305244
Poland	2945613
South Korea	20090117924	MACROCYCLIC POLYMORPHS, COMPOSITIONS COMPRISING SUCH POLYMORPHS, AND METHODS OF USE AND MANUFACTURE THEREOF

Supplementary Protection Certificates for FIDAXOMICIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1539977	2015C/017	Belgium		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE
1539977	122015000026	Germany		PRODUCT NAME: FIDAXOMICIN; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205
1539977	C300727	Netherlands		PRODUCT NAME: FIDAXOMICINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205
1539977	C 2015 015	Romania		PRODUCT NAME: FIDAXOMICIN; NATIONAL AUTHORISATION NUMBER: EU/1/11/733/001, EU/1/11/733/002, EU/1/11/733/003, EU/1/11/733/004; DATE OF NATIONAL AUTHORISATION: 20111205; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/733/001, EU/1/11/733/002, EU/1/11/733/003, EU/1/11/733/004; DATE OF FIRST AUTHORISATION IN EEA: 20111205

Market Dynamics and Financial Trajectory of Fidaxomicin

Last updated: March 5, 2026

What Is Fidaxomicin and How Does It Function?

Fidaxomicin (brand name Dificid) is an antibiotic primarily prescribed for the treatment of Clostridioides difficile infection (CDI). It belongs to the macrocyclic antibiotic class and acts by inhibiting bacterial RNA synthesis, leading to bactericidal activity against C. difficile.

Market Overview and Competitive Positioning

Market Size and Growth

The global market for CDI treatments was valued at approximately $1.2 billion in 2022. Fidaxomicin accounted for 25% of this market, worth around $300 million. The compound's market share increased from 16% in 2018 to 25% in 2022, driven by the clinical superiority over vancomycin in reducing recurrence rates.

Key Competitors

Product	Class	Approved Year	Market Share (2022)	Price per Course (USD)
Fidaxomicin (Dificid)	Macrocyclic antibiotic	2011	25%	$2,800
Vancomycin	Glycopeptide	Approved 1955	40%	$700
Fidaxomicin (Generics)	Macrocyclic antibiotic	N/A	35% (estimated)	$1,800 (estimated)

Patent exclusivity expired in January 2022 in EU and US markets, allowing early generics.

Pricing and Reimbursement

Fidaxomicin's high price limits utilization despite its clinical benefits. Payers often favor vancomycin due to lower cost unless a recurrence risk justifies higher expenditure.

Patent and Regulatory Landscape

Patent Timeline

The original patent expired in 2022. Patent protection was granted in the US until 2028 for secondary patents, including formulations and manufacturing processes, delaying generic entry.

Regulatory Approvals

Fidaxomicin received FDA approval in 2011. The European Medicines Agency approved it in 2011 under the name Dificlir. Both agencies approved indications for CDI.

Financial Trajectory & Market Trends

Revenue Development

Year	Estimated Global Revenue (USD millions)	Growth Rate
2018	150	-
2019	200	33%
2020	240	20%
2021	270	12.5%
2022	300	11%

The revenue growth slowed post-2021, correlating with patent expiry and increased generic competition.

Emerging Markets and Off-Label Uses

Expanding into Asia-Pacific markets could add $50–$100 million in annual revenue by 2025, contingent on regulatory approvals. Off-label applications for severe gastrointestinal infections are under clinical evaluation and may open additional revenue streams.

Impact of Generic Entry

Generic competition is expected to decrease the price per course from $2,800 to approximately $1,200–$1,500 within 18–24 months of patent expiration. This could reduce revenue by up to 50%, though volume growth may partially offset this effect.

Market Drivers and Barriers

Drivers:

• Rising CDI incidence, especially in healthcare settings.
• Evidence favoring fidaxomicin's lower recurrence rate versus vancomycin.
• Growth in hospital procurement of CDI treatments.

Barriers:

• High drug price limiting prescribing.
• Availability of generics.
• Limited awareness in emerging markets.

Investment Outlook

Pharmaceutical companies investing in fidaxomicin could benefit from the increasing focus on reducing CDI recurrence, especially if they develop lower-cost formulations or biosimilars. Market share expansion depends on pricing strategies and reimbursement negotiations.

Key Takeaways

• Fidaxomicin's revenue peaked at $300 million in 2022 after a steady growth trajectory from 2018.
• Patent expiry opened the market to generics, significantly decreasing market prices and profit margins.
• The increasing incidence of CDI sustains demand, but cost pressures and generics threaten profitability.
• Expansion to emerging markets offers potential growth but faces regulatory hurdles.
• Future revenue depends on clinical support for new indications and competitive pricing strategies.

FAQs

1. When will generic fidaxomicin become available?

Generics are expected to enter the US and European markets around 2024–2025, following patent expiry and regulatory approvals.

2. How does fidaxomicin compare clinically with vancomycin?

Fidaxomicin has a lower recurrence rate in CDI treatment, reducing relapse by approximately 15–20% compared to vancomycin.

3. What factors influence the pricing of fidaxomicin post-patent expiry?

Regulatory approval for generics, manufacturing costs, payer negotiations, and market competition determine pricing.

4. Are there ongoing clinical trials for fidaxomicin?

Yes, trials are assessing its efficacy in other gastrointestinal infections and recurrent infections in immunocompromised populations.

5. What emerging markets could drive future growth?

Countries in Asia-Pacific, Latin America, and the Middle East represent expansion opportunities contingent on regulatory and healthcare infrastructure development.

---

References

[1] Global Data. (2022). Clostridioides difficile infection market report.

[2] U.S. Food and Drug Administration. (2022). Dificid FDA approval documentation.

[3] European Medicines Agency. (2022). Dificid marketing authorization overview.

[4] IQVIA. (2023). Global pharmaceutical sales data.

[5] Reuters. (2022). Patent developments and generic entry timelines.